奥沙利铂：分子靶向治疗时代的回顾。
Oxaliplatin: a review in the era of molecularly targeted therapy.
机构信息
McGill University Departments of Oncology and Medicine, Montreal, QC.
出版信息
Curr Oncol. 2011 Jan;18(1):18-25. doi: 10.3747/co.v18i1.708.
Abstract
OBJECTIVE
To review preclinical and clinical data for oxaliplatin in the current context of molecularly targeted therapy.
METHODS OF STUDY SELECTION
We searched the PubMed and PubChem databases by combining the search terms "oxaliplatin" or "platinum" or both, with "clinical trials," "pharmacokinetics," and "pharmacodynamics."
DATA EXTRACTION AND SYNTHESIS
Oxaliplatin has a complicated pharmacokinetic profile, with activity against digestive cancers in particular. It has several mechanisms of action, but cancer cells can develop resistance. Real or potential synergism has been observed when oxaliplatin is combined with other cytotoxic agents or molecularly targeted agents. Peripheral neuropathy is a prominent toxic effect.
CONCLUSIONS
Oxaliplatin lends itself to further clinical research in combination with molecularly targeted therapy.
摘要
目的
在分子靶向治疗的背景下，综述奥沙利铂的临床前和临床数据。
研究选择方法
我们通过将搜索词“奥沙利铂”或“铂”或两者与“临床试验”、“药代动力学”和“药效学”相结合，在 PubMed 和 PubChem 数据库中进行搜索。
数据提取和综合
奥沙利铂具有复杂的药代动力学特征，对消化道癌症尤其有效。它有几种作用机制，但癌细胞可以产生耐药性。当奥沙利铂与其他细胞毒性药物或分子靶向药物联合使用时，观察到了真正或潜在的协同作用。周围神经病变是一种突出的毒性作用。
结论
奥沙利铂适合与分子靶向治疗进一步进行临床研究。
相似文献
1
Oxaliplatin: a review in the era of molecularly targeted therapy.
Curr Oncol. 2011 Jan;18(1):18-25. doi: 10.3747/co.v18i1.708.
2
Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Clin Pharmacokinet. 2000 Jan;38(1):1-21. doi: 10.2165/00003088-200038010-00001.
3
Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Drugs. 2000 Oct;60(4):895-924. doi: 10.2165/00003495-200060040-00005.
4
Oxaliplatin: a review of preclinical and clinical studies.
Ann Oncol. 1998 Oct;9(10):1053-71. doi: 10.1023/a:1008213732429.
5
Pharmacokinetics and safety profile of oxaliplatin.
Semin Oncol. 1998 Apr;25(2 Suppl 5):13-22.
6
Cellular and molecular pharmacology of oxaliplatin.
Mol Cancer Ther. 2002 Jan;1(3):227-35.
7
Different infusion durations for preventing platinum-induced hearing loss in children with cancer.
Cochrane Database Syst Rev. 2016 Aug 8(8):CD010885. doi: 10.1002/14651858.CD010885.pub3.
8
Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Clin Lung Cancer. 2010 Jan;11(1):18-24. doi: 10.3816/CLC.2010.n.003.
9
[Oxaliplatin: the first DACH platinum in clinical practice].
Bull Cancer. 1997 Jun;84(6):665-73.
10
Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.
J Clin Oncol. 1999 Jun;17(6):1751-9. doi: 10.1200/JCO.1999.17.6.1751.
引用本文的文献
1
Cilastatin Modulates DPEP1- and IQGAP1-Associated Neuro-Glio-Vascular Inflammation in Oxaliplatin-Induced Peripheral Neurotoxicity.
Cells. 2025 Aug 20;14(16):1294. doi: 10.3390/cells14161294.
2
Targeting cytokine and chemokine signaling pathways for enhancing chemo-sensitivity in colorectal cancer.
Cell Commun Signal. 2025 Aug 12;23(1):369. doi: 10.1186/s12964-025-02235-7.
3
Transcriptomic Landscape of Paclitaxel-Induced Multidrug Resistance in 3D Cultures of Colon Cancer Cell Line DLD1.
Int J Mol Sci. 2025 Jul 9;26(14):6580. doi: 10.3390/ijms26146580.
4
Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies.
Med Oncol. 2025 Jun 16;42(7):262. doi: 10.1007/s12032-025-02812-3.
5
HGF/c-Met Axis-Targeted Nanotherapy via GSH-Responsive Polymer Platforms Suppresses Uveal Melanoma Metastasis.
Adv Healthc Mater. 2025 Jun;14(15):e2405056. doi: 10.1002/adhm.202405056. Epub 2025 May 8.
6
Analgesic and neuroprotective effect of a lipid transfer protein isolated from Morinda citrifolia L. (noni) seeds on oxaliplatin-induced peripheral sensory neuropathy in mice.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 30. doi: 10.1007/s00210-025-04216-6.
7
Subcellular localisation and identification of single atoms using quantitative scanning transmission electron microscopy.
J Microsc. 2025 Jul;299(1):36-48. doi: 10.1111/jmi.13410. Epub 2025 Apr 15.
8
Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.
Cancer Drug Resist. 2025 Feb 8;8:7. doi: 10.20517/cdr.2024.164. eCollection 2025.
9
Patient-derived tumor xenograft animal model of gastric cancer in precision chemotherapy.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb 19. doi: 10.1007/s00210-025-03903-8.
10
Predicting patient outcomes with gene-expression biomarkers from colorectal cancer organoids and cell lines.
Front Mol Biosci. 2025 Jan 15;12:1531175. doi: 10.3389/fmolb.2025.1531175. eCollection 2025.
本文引用的文献
1
Treatment-related toxicity and supportive care in metastatic colorectal cancer.
J Support Oncol. 2010 Jan-Feb;8(1):15-20.
2
Inhibition of transcription by platinum antitumor compounds.
Metallomics. 2009;1(4):280-91. doi: 10.1039/b907567d.
3
Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study.
Gynecol Oncol. 2010 Mar;116(3):442-6. doi: 10.1016/j.ygyno.2009.10.082. Epub 2009 Nov 20.
4
Immunogenic death of colon cancer cells treated with oxaliplatin.
Oncogene. 2010 Jan 28;29(4):482-91. doi: 10.1038/onc.2009.356. Epub 2009 Nov 2.
5
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18.
6
Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450.
Anticancer Drugs. 2009 Jun;20(5):305-11. doi: 10.1097/cad.0b013e328323a7a8.
7
Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
Anticancer Drugs. 2009 Feb;20(2):105-8. doi: 10.1097/CAD.0b013e32831cdb51.
8
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268.
9
Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies.
Curr Med Chem. 2008;15(29):3081-94. doi: 10.2174/092986708786848569.
10
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
BMC Clin Pharmacol. 2008 Sep 17;8:7. doi: 10.1186/1472-6904-8-7.
Zotero 插件